Antibody B4 targets an annexin IV neoepitope which is exposed upon oxidative stress and/or smoke exposure in animal AMD models; B4-scFv-fH effectively reduced complement activation in two mouse models of retinal degeneration, suggesting that it may be a promising candidate for a future therapeutic agent (257). This evidence concerns the gene FH and age-related macular degeneration.